What is the Nexturn Bioscience Co., Ltd. stock price forecast?

Nexturn Bioscience Co., Ltd. is currently trading at ₩2,715. View real-time AI analysis on Alpha Lenz.

What is Nexturn Bioscience Co., Ltd. insider trading activity?

View the latest insider trading data for Nexturn Bioscience Co., Ltd. on Alpha Lenz.

What is Nexturn Bioscience Co., Ltd.'s P/E ratio?

Nexturn Bioscience Co., Ltd.'s P/E ratio is -4.3.

Nexturn Bioscience Co., Ltd.

KRX · 089140

₩2,715+445(+19.60%)Market closed

Ask about Nexturn Bioscience Co., Ltd.'s future dividend policy...

Alpha Chat Insight

“Nexturn Bioscience Co., Ltd. trades at a P/E of -4.3 (undervalued) with modest ROE of -7.1%. 3Y revenue CAGR of 44.3% highlights clear growth momentum.”

Ask for details →

Company Overview

Nexturn Bioscience Co., Ltd. is a prominent entity in the biotechnology sector, primarily focusing on the development and production of advanced biopharmaceutical products. The company specializes in the research and manufacturing of pharmaceutical ingredients that are integral to innovative therapeutic solutions. Its operations emphasize the creation of active compounds for use in various medical treatments, contributing significantly to healthcare advancements. Nexturn Bioscience plays a crucial role in the biotechnology industry by addressing critical health needs and enhancing patient care. This company is vital in the pharmaceutical supply chain, supporting both small biotech firms and large pharmaceutical companies. Through sustained R&D efforts, Nexturn Bioscience contributes to the discovery and refinement of life-saving drugs and therapies, reinforcing its reputation as a key player in the medical advancement landscape.

CEO이주한

Websitehttps://www.nexturn.co.kr

SectorCommon Stock

IndustryCommon Stock

Company Statistics

FY 2025

Profile

₩41,583,575,310Market Cap

₩70,440,930,510Revenue

15.32MShares Out

0Employees

Margins

29.05%Gross

5.87%EBITDA

3.26%Operating

-8.74%Pre-Tax

-3.33%Net

Valuation

-4.29P/E

0.31P/B

0.59EV/Sales

49.74EV/EBITDA

-6.71P/FCF

Growth (CAGR)

44.26%Rev 3Yr

48.71%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-0.82%ROA

-7.13%ROE

-0.33%ROIC

Financial Health

₩20,006,120,470Cash & Cash Equivalents

₩98,390,869,250Net Debt

53.21%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Nexturn Bioscience Co., Ltd. trades at a P/E of -4.3 (undervalued) with modest ROE of -7.1%. 3Y revenue CAGR of 44.3% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Nexturn Bioscience Co., Ltd. (ticker: 089140) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $41.6B.

The current price is ₩2,715 with a P/E ratio of -4.29x and P/B of 0.31x.

ROE is -7.13% and operating margin is 3.26%. Annual revenue is $70.4B.